Translational Cancer Genomics

Group leader: Zoltan Szallasi

Translational Cancer Genomics

DNA repair pathway aberrations emerged as a major therapeutically targetable feature of human cancer. However, it is not trivial how to identify and quantify those in human cancer biopsies. Our group has developed several next-generation sequencing based methods to achieve this, with some of those reaching the clinical application stage. Our methods are essential for the optimal application of PARP inhibitor based therapy.

Cancer immunology has provided major breakthroughs in the treatment of advanced, metastatic cancer. However, we have only limited understanding of the mechanism of action of immunology based therapy and we do not understand why only certain patients respond. In collaboration with Herlev Hospital (Center for Cancer Immune Therapy) we are combining next generation sequencing based approaches with translational oncology research to improve the efficacy of cancer immunotherapy.

Group members

Postdoc Zsófia Márta Sztupinski 
PhD student Judit Börcsök 

Selected publications:

Poti, A., Berta, K., Xiao, Y., Pipek, O., Klus, G. T., Ried, T., Csabai, I., Wilcoxen, K., Mikule, K., Szallasi, Z., Szuts, D.
Long-term treatment with the PARP inhibitor niraparib does not increase the mutation load in cell line models and tumour xenografts.
Br.J.Cancer 2018: 119(11), 1392-1400

Sztupinszki, Z., Diossy, M., Krzystanek, M., Reiniger, L., Csabai, I., Favero, F., Birkbak, N. J., Eklund, A. C., Syed, A., Szallasi, Z.
Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer.
NPJ.Breast Cancer 2018: 4, 16

Diossy, M., Reiniger, L., Sztupinszki, Z., Krzystanek, M., Timms, K. M., Neff, C., Solimeno, C., Pruss, D., Eklund, A. C., Toth, E., Kiss, O., Rusz, O., Cserni, G., Zombori, T., Szekely, B., Timar, J., Csabai, I., Szallasi, Z.
Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors.
Ann.Oncol. 2018: 29(9), 1948-1954

Birkbak, N. J., Li, Y., Pathania, S., Greene-Colozzi, A., Dreze, M., Bowman-Colin, C., Sztupinszki, Z., Krzystanek, M., Diossy, M., Tung, N., Ryan, P. D., Garber, J. E., Silver, D. P., Iglehart, J. D., Wang, Z. C., Szuts, D., Szallasi, Z., Richardson, A. L.
Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple-negative breast and serous ovarian cancers.
Ann.Oncol. 2018: 29(4), 903-909